Shares of Cerulean Pharma Inc. (CERU) are higher by more than 4% to $11.12 in after-hours trading on Thursday, after the company announced phase 1b/2 trial of CRLX101 in combination with Avastin in relapsed renal cell carcinoma met primary endpoint.
“The top-line results from this trial in a difficult-to-treat patient population are encouraging,” said in a statement Paul Friedman, M.D., Executive Chairman at Cerulean. “The median [progression free survival] PFS of 9.9 months supports the rationale for our ongoing randomized Phase 2 trial of CRLX101 plus Avastin in 3rd and 4th line RCC.”
Fundamentally, CERU shows the following financial data:
- $57.79 million in cash in most recent quarter
- $6.83 million t-12 total assets
- ($12.77) million total equity
- $86.00K t-12 revenue
- ($16.91) million annual net income
- ($16.62) million free cash flow
On valuation measures, Cerulean Pharma Inc. shares have a T-12 price/sales ratio of 2,159 and a price/book for the same period of 3.54. EPS is ($1.16). The name has a market cap of $203.93 million and a median Wall Street price target of $12.50 with a high target of $14.00. Currently there are 4 analysts that rate CERU a ‘Buy’. No analyst rates it a ‘Hold’ or a ‘Sell’.
In terms of share statistics, Cerulean Pharma Inc. has a total of 20.13 million shares outstanding with 55.51% held by insiders and 2.80% held by institutions. The stock’s short interest currently stands at 0.54%, bringing the total number of shares sold short to 45,458.
Shares of the Cambridge Massachusetts-based company are up 52.68% year-over-year and 48.39% year-to-date.
Cerulean Pharma Inc is a clinical-stage Cambridge, Massachusetts-based company that focuses on developing nanopharmaceutical product candidates in the areas of oncology and other diseases in the United States.